Canadian Pacific Kansas City Limited Common Shares vs Smith & Nephew plc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $83.86 (market cap $73.71B), while Smith & Nephew plc trades at $26.9 (market cap $11.31B). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 6.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| CP | SNN | |
|---|---|---|
Market Cap | $73.71B | $11.31B |
Volume | 2,143,178 | 1,050,005 |
Sector | Industrials | Health |
52-Week High | $96.69 | $37.17 |
52-Week Low | $68.88 | $26.42 |
Enterprise Value | $91.14B | $14.35B |
Dividend Yield | 0.91% | 2.95% |
Typical Hold Time | — | 120 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Trailing returns across standard periods
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →